Your browser doesn't support javascript.
loading
CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling.
Moutal, Aubin; Honnorat, Jérôme; Massoma, Patrick; Désormeaux, Pauline; Bertrand, Caroline; Malleval, Céline; Watrin, Chantal; Chounlamountri, Naura; Mayeur, Marie-Eve; Besançon, Roger; Naudet, Nicolas; Magadoux, Léa; Khanna, Rajesh; Ducray, François; Meyronet, David; Thomasset, Nicole.
Afiliação
  • Moutal A; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France.
  • Honnorat J; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France.
  • Massoma P; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France.
  • Désormeaux P; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France.
  • Bertrand C; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France.
  • Malleval C; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France.
  • Watrin C; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France.
  • Chounlamountri N; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France.
  • Mayeur ME; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France.
  • Besançon R; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France.
  • Naudet N; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France.
  • Magadoux L; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France.
  • Khanna R; Department of Pharmacology and Neuroscience Graduate Interdisciplinary Program, College of Medicine, University of Arizona, Tucson, Arizona.
  • Ducray F; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France. Hospices Civils de Lyon, Neuro-Oncology, Lyon, France.
  • Meyronet D; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France. Hospices Civils de Lyon, Centre de Pathologie et de Neuropathologie Est, Lyon, France.
  • Thomasset N; INSERM U1028, CNRS UM5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, University Claude Bernard Lyon 1, Lyon, France. nicole.thomasset@inserm.fr.
Cancer Res ; 75(17): 3519-28, 2015 Sep 01.
Article em En | MEDLINE | ID: mdl-26122847
ABSTRACT
Collapsin response mediator protein 5 (CRMP5) belongs to a family of five cytosolic proteins that play a major role in nervous system development. This protein was first described in cancer-induced autoimmune processes, causing neurodegenerative disorders (paraneoplastic neurologic syndromes). CRMP5 expression has been reported to serve as a biomarker for high-grade lung neuroendocrine carcinomas; however, its functional roles have not been examined in any setting of cancer pathophysiology. In this study, we report two different CRMP5 expression patterns observed in human glioblastoma (GBM) biopsies that establish connections between CRMP5 expression, Notch receptor signaling, and GBM cell proliferation. We demonstrated that elevated CRMP5 promotes Notch receptor expression and Akt activation in human tumor cell lines, GBM stem cells, and primary tumor biopsies. We have shown that the high CRMP5 and Notch expression in GBM xenograft is related to stem cells. This suggests that high CRMP5 expression pattern in GBM biopsies encompasses a subset of stem cells. Mechanistically, CRMP5 functioned by hijacking Notch receptors from Itch-dependent lysosomal degradation. Our findings suggest that CRMP5 serves as a major mediator of Notch signaling and Akt activation by controlling the degradation of the Notch receptor, with implications for defining a biomarker signature in GBM that correlates with and may predict patient survival.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Receptores Notch / Proteínas do Tecido Nervoso Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Res Ano de publicação: 2015 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Receptores Notch / Proteínas do Tecido Nervoso Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Res Ano de publicação: 2015 Tipo de documento: Article País de afiliação: França